NAKIA SIMON: Open Payments
NPI 1013336148 · LYNWOOD, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,686 in 34 payments from 8 companies in 2025. Trend: 2023 $667 · 2024 $1,318 · 2025 $1,686
Food & beverage: $1,686
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $449 |
| Janssen Pharmaceuticals, Inc | 5 | $328 |
| Alkermes, Inc. | 11 | $320 |
| Teva Pharmaceuticals USA, Inc. | 3 | $158 |
| E.R. Squibb & Sons, L.L.C. | 4 | $157 |
| Neurocrine BioSciences, Inc. | 1 | $150 |
| Otsuka America Pharmaceutical, Inc. | 3 | $84 |
| Axsome Therapeutics, Inc. | 2 | $41 |
Products named: CAPLYTA, INVEGA SUSTENNA, ARISTADA, COBENFY, INGREZZA, UZEDY, LYBALVI, Auvelity.
Industry payments across CA — which companies pay providers there.
